Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 105,200
  • Shares Outstanding, K 116,128
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,760 K
  • EBIT $ -29 M
  • EBITDA $ -29 M
  • 60-Month Beta 0.98
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.29
  • Most Recent Earnings $-0.08 on 03/30/26
  • Next Earnings Date 05/13/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.06
  • Number of Estimates 2
  • High Estimate $-0.06
  • Low Estimate $-0.06
  • Prior Year $-0.06
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7800 +19.42%
on 03/30/26
1.0800 -13.75%
on 03/10/26
-0.1285 (-12.12%)
since 03/09/26
3-Month
0.7800 +19.42%
on 03/30/26
1.3000 -28.35%
on 01/22/26
-0.0362 (-3.74%)
since 01/09/26
52-Week
0.3258 +185.91%
on 06/06/25
1.5100 -38.31%
on 09/29/25
+0.4118 (+79.24%)
since 04/09/25

Most Recent Stories

More News
Stocks in play: Oncolytics Biotech Inc

Announced it has scheduled a Type C meeting with the U.S. Food and Drug Administration on April 16, ...

ONCY : 0.9714 (+7.23%)
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, an investigational,...

ONCY : 0.9714 (+7.23%)
Stocks in play: Oncolytics Biotech Inc

Announced the completion of the previously announced change in the jurisdiction of incorporation of ...

ONCY : 0.9714 (+7.23%)
Oncolytics Biotech® Completes Domicile Change to the United States

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced...

ONCY : 0.9714 (+7.23%)
Stocks in play: Oncolytics Biotech Inc

Announced two abstracts across distinct tumor types were accepted for presentation at the American Association ...

ONCY : 0.9714 (+7.23%)
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026

Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure formation  Translational data suggest potential to boost response to immunotherapy and targeted therapy in...

ONCY : 0.9714 (+7.23%)
Stocks in play: Oncolytics Biotech Inc

Announced the initiation of a metastatic colorectal cancer Phase 2 study that will be referred to as ...

ONCY : 0.9714 (+7.23%)
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study

Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L...

ONCY : 0.9714 (+7.23%)
Stocks in play: Oncolytics Biotech Inc

Announced it has concluded enrollment in the GOBLET study, having generated the necessary clinical and ...

ONCY : 0.9714 (+7.23%)
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer

Company to wind down the GOBLET gastrointestinal study to focus on registration path in the U.S. With sufficient cash on hand to execute near-term milestones, the Company expects to avoid immediate...

ONCY : 0.9714 (+7.23%)

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

3rd Resistance Point 0.9539
2nd Resistance Point 0.9420
1st Resistance Point 0.9239
Last Price 0.9714
1st Support Level 0.8939
2nd Support Level 0.8820
3rd Support Level 0.8639

See More

52-Week High 1.5100
Fibonacci 61.8% 1.0576
Last Price 0.9714
Fibonacci 50% 0.9179
Fibonacci 38.2% 0.7782
52-Week Low 0.3258

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.